Recursion Clinical Trial, CRISPR Delivery methods, preclinical Cas12 use, Gene Editing in AgBio, Top 10 Takeover Targets

Season 2 Episode 1 (February 14, 2025): This week, the GEN editors discussed some interesting and developing stories around AI, including an in depth dialogue about what Recursion has been doing lately. They also discussed gene editing updates in delivery systems, Cas12 preclinical work, and AgBio. The discussion was rounded out with a look forward into takeover targets for 2025.

Featuring Alex Philippidis (Senior Business Editor, GEN), Fay Lin, PhD, (Editor, GEN Biotechnology), Uduak Thomas (Senior Editor, GEN), and moderated by Corinna Singleman, PhD, (Managing Editor, GEN and IPM)

Listed below are key references to the GEN stories, media, and other items discussed in this episode of Touching Base:

As Pipeline Advances, Recursion Expands AI Focus to Clinical Trials

By Alex Phillipidis, GEN, Jan 30, 2025.

Recursion Announces Promising Clinical Data on Lead AI-Based Drug Candidate for Brain Disease

By Fay Lin, PhD, GEN Edge, Feb 5, 2025.

AAV Delivered NanoCas CRISPR System Edits Muscle in Non-Human Primates

By GEN, Feb 3, 2025.

Next-Gen Cas12a System Enables Precise Single and Multiplexed Gene Editing in Cancer

By Corinna Singleman, PhD, GEN, Jan 30, 2025.

AgBio Companies Embrace Gene Editing for Stronger Food Future

By Uduak Thomas, GEN Feb issue, Feb 3, 2025.

Top 10 Takeover Targets of 2025